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Introduction
Glaucoma is characterized by the loss of  retinal ganglion cells and 
associated axons, which becomes clinically manifest in visual field 
deterioration [1]. Given that increased intraocular pressure (IOP) 
is the most important risk factor for the development and pro-
gression of  the disease [2], lowering of  the IOP is currently the 
only proven therapy for the treatment of  glaucoma. This has been 
demonstrated in several large interventional studies, showing that 
lowering IOP slows down the progression of  the disease [3].
Although for a long time, beta-blockers were the mainstay of  
therapy aiming to lower IOP, prostaglandin analogues are more 
and more often used as the first-line therapy in the treatment of  
primary open-angle glaucoma. Prostaglandin analogues are known 
for their potent IOP lowering effect by increasing the aqueous hu-
mor outflow [4]. In addition, prostaglandin analogues show only 
a low risk of  side effects and allow for a once-a-day instillation, 
both of  which are major determinants of  patients´ compliance.
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Abstract
Purpose: Increased intraocular pressure (IOP) is the most important modifiable risk factor for the development and pro-
gression of  glaucoma. This underlines the need for a potent and save IOP lowering therapy. The introduction of  preserva-
tive free prostaglandins offers a new treatment possibility using a potent topical drug without the disadvantages of  a co-
administered preservative. The current study was designed to investigate the effect of  an 8 week treatment with preservative 
free tafluprost on IOP in patients with glaucoma or ocular hypertension.
Methods: 16 patients with either primary open angle glaucoma or ocular hypertension with an uncontrolled intraocular 
pressure (IOP) ≥ 30mmHg were included in the study. A washout period with a duration between 2 and 4 weeks was sched-
uled for all patients before study start. IOP was measured at 8:00am and 6:00pm on each study day. IOP measurements were 
performed after the washout period as well as 4 and 8 weeks after start of  topical drug treatment. 
Results: After the 2-4 weeks washout period average IOP was 35.6±4.5 mmHg at 8:00 am and 32.9±5.4 mmHg at 6:00 pm. 
After 4 weeks administration of  preservative free tafluprost, IOP decreased by 31% ± 12% to 24.4±4.6 mmHg (p<0.01) 
and by 34% ± 14% to 21.6±4.6 mmHg (p<0.01) at the morning and evening, respectively. At 8 weeks of  tafluprost treat-
ment IOP was 24.3±4.6 mmHg at 8:00 am(-31% ± 13% compared to baseline, p<0.01) and 21.9±3.9 mmHg at 6:00 pm 
(-32% ± 16% compared to baseline, p<0.01). No significant difference was observed in IOP change between 4 and 8 weeks 
at either time point.
Conclusion: Our data indicate that treatment with preservative free tafluprost is a safe and potent therapy to lower IOP in 
patients with primary open angle glaucoma and ocular hypertension. In this group of  patients with relatively high IOPs at 
baseline a pronounced reduction of  IOP was achieved over a period of  4 to 8 weeks.
Key Words: Glaucoma; Intraocular Pressure; Ocular Hypertension; Preservative-Free; Tafluprost.
Garhofer G, et al., (2015) The Effect of  Preservative Free Tafluprost on Intraocular Pressure in Patients with Ocular Hypertension or Primary Open Angle Glaucoma. 
Int J Ophthalmol Eye Res. S1:006, 27-31 28
                http://scidoc.org/IJOES.php
Although prostaglandins have proven to be safe and well toler-
ated, data from clinical studies indicate that preservatives, which 
are added to multi-dose bottles to inhibit the growth of  microbial 
contaminants, may have adverse effects in long term use [5]. In 
particular, benzalkonium chloride may affect the ocular surface 
and exacerbate symptoms of  chronic ocular surface disease [6]. 
Recently, the introduction of  preservative free prostaglandin ana-
logues has offered the possibility of  topical prostaglandin treat-
ment without the concomitant use of  preservatives [7]. In this 
study we focus on the IOP lowering potency of  tafluprost pre-
servative free eyedrops in patients with ocular hypertension and 
with primary open angle glaucoma and an untreated IOP of  30 
mmHg and more.
Materials and Methods
Patients
The study protocol was approved by the Ethics Committee of  
the City of  Vienna and followed the guidelines of  Good Clinical 
Practice and the Declaration of  Helsinki. 16 patients with either 
primary open angle glaucoma or patients with ocular hyperten-
sion were included in the study. All patients signed a written in-
formed consent form and passed an ophthalmologic examination 
including gonioscopy and visual field testing with the Octopus 
Perimeter. Patients with ocular disease other than glaucoma or 
ocular hypertension were excluded from the study. Further, pa-
tients with topical treatment with any ophthalmic drug in the 4 
weeks preceding the first study visit except glaucoma medication 
or topical lubricants were not included in the study.
Inclusion and Exclusion Criteria
Patients with primary open angle glaucoma (POAG): Inclu-
sion criteria were POAG defined as pathological optic disc ap-
pearance and characteristic visual field loss, ametropia of  less than 
3 diopters, and anisometropia of  less than 1 diopter. Only pa-
tients with an untreated IOP of  30 mmHg or more were included 
in the study. Any of  the following excluded a glaucoma patient 
from participation in the trial: exfoliation glaucoma, pigmentary 
glaucoma, history of  acute angle closure, mean deviation (MD) of  
visual field testing of  15 dB or worse or intraocular surgery within 
the last 6 months.
Patients with ocular hypertension: Ocular hypertension was 
defined as an untreated IOP of  30 mmHg or more without any 
glaucomatous changes in either the visual field or the optic disc 
appearance.
Experimental Paradigm
For eligible patients, current ocular hypotensive treatment was 
suspended prior to the baseline visit for 2 to 4 weeks if  applicable. 
Three study visits were scheduled for all participating patients. At 
each visit, IOP was measured twice in the study eye at 8:00 am 
and 6:00 pm.
Intraocular pressure
A slit-lamp mounted Goldmann applanation tonometer (Haag 
Streit, Switzerland) was used to measure IOP. Before each meas-
urement, one drop of  0.4 % benoxinate hydrochloride combined 
with 0.25 % sodium fluorescein was used for local anesthesia of  
the cornea. All IOP measurements were performed by the same 
person.
Pachymetry
Corneal thickness was determined by a pachymeter (Pachette II, 
DGH Technology Inc., USA). Using an ultrasound probe at a 
frequency of  65MHz, the pachymeter is able to determine the 
thickness of  the cornea in any given location. The probe touches 
the corneal surface under local anesthesia.
Statistics
Data are presented as means ± SD. Statistical analysis was done 
as a “per protocol” analysis. Statistical significant effects were 
assessed within a repeated measures ANOVA model. A p<0.05 
was considered as the level of  significance. Calculations were per-
formed using the Statistica® software package (Statsoft, USA).
Results
16 patients (mean age 62.3 ± 11.8 years) were included in the 
study. Baseline characteristics of  the patients are given in Table 1.
After the 2-4 week washout period average IOP was 35.6±4.5 
mmHg at the morning and 32.9±5.4 mmHg at the evening meas-
urement. As shown in figures 1 and 2, 4 weeks after the start 
of  treatment preservative free tafluprost decreased IOP by 
31%±12% to 24.4±4.6 mmHg (p<0.01) at the morning and by 
34%±14% to 21.6±4.6 mmHg (p<0.01) at the evening.
8 weeks after start of  treatment, IOP was still low, amounting 
to 24.3±4.6 mmHg (-31%±13% compared to baseline, p<0.01) 
in the morning and 21.9±3.9mmHg (-32%±16% compared to 
baseline, p<0.01) in the evening (Figures 1 and 2). No signifi-
cant difference was observed in terms of  IOP change between 
4 and 8 weeks of  treatment at neither of  the two measurement 
times (p=0.9 for the morning measurement; p=0.8 for the even-
ing measurement).
No serious adverse events were observed. A total of  12 adverse 
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Table 1. Baseline characteristics of  the study population at the screening examination. Values are given as means ± SD.
Age (years) 62.3 ± 11.8
Mean deviation (dB) 1.4 ± 3.7
Intraocular pressure (mmHg) 28 ± 5
Central corneal thickness (µm) 543 ± 43
Gonioscopy grading (Shaffer classification) 3.6 ± 0.5
Visual acuity (Snellen) 0.73 ± 0.21
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events occurred in 8 of  the 16 patients during the study. All events 
were mild and 4 were judged as possibly related and 1 as unlikely 
related to the study medication. All other adverse events were 
judged as not related to the study medication. A listing of  all ad-
verse events observed is given in Table 2.
Discussion
Given that IOP lowering therapy is usually a life-time or at least 
a long-time treatment, preservative free prostaglandin treatment 
offers several major advantages for patients. These advantages 
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Figure 1. Intraocular pressure during the course of  the study (* significant changes vs. baseline). Values are shown as 
means ± SD
Figure 2. Relative change in intraocular pressure after 4 and 8 weeks compared to baseline (* significant changes vs. base-
line). Values are shown as means ± SD.
Table 2. Summary of  all Adverse Events that occurred during the study.
Adverse Event Times observed Severity Relationship to Medication
Ocular Adverse Events
Itching after instillation 1 Mild Possible
Hyperemia in both eyes 1 Mild Possible
Burning after instillation 1 Mild Possible
Light sensitivity 1 Mild Possible
Blepharitis 1 Mild Unlikely
Non-ocular Adverse Events
Common cold 2 Mild Unrelated
Rhinitis 2 Mild Unrelated
Gingivitis 1 Mild Unrelated
Stomal mucosa wound 1 Mild Unrelated
Exanthema and pruritus (limbs) 1 Mild Unrelated
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include a reduced exposure to preservatives, enhanced patient 
compliance and a reduction of  the number of  drops instilled [8, 
9]. The data of  the current study confirms that treatment with 
preservative free tafluprost eye drops is safe and leads to a pro-
nounced reduction in IOP even in patients with IOP levels of  30 
mmHg or higher.
In the last years evidence has accumulated that long-term treat-
ment with preservative containing eye drops may have adverse 
effects on the eye and especially on the ocular surface. Nowadays 
it is well established that most of  the observed side effects are re-
lated rather to the concomitant application of  preservatives, most 
importantly to benzalkonium chloride, than to the active ingredi-
ent itself. This is also underlined by the observation that most side 
effects seen in glaucoma patients are more frequent in patients 
taking preservative containing eye drops compared to those tak-
ing preservative free formulations [10].
However, as it is known that benzalkonium chloride acts as a pen-
etration enhancer for drugs into the anterior chamber of  the eye, 
doubts have been raised concerning the clinical efficacy of  IOP 
lowering drugs without preservatives [11]. It has been shown that 
benzalkonium chloride when added to a topical formulation, in-
creases the penetration of  certain compounds through the cornea 
[12]. It has, however, to be noted that changed penetration of  
a compound though the cornea does not necessary correlate to 
its clinical efficacy An experimental study in rabbits has shown 
that for tafluprost, there is no difference in the penetration into 
the anterior chamber between benzalkonium chloride containing 
and preservative free formulations [13]. Still, clinical studies are 
necessary to assess the IOP lowering potential of  preservative 
free formulations in a clinical “real life” setting. A cross-sectional 
study investigating the effect of  4 weeks treatment with a pre-
served and a preservative-free tafluprost formulation in patients 
with POAG or ocular hypertension found no differences in terms 
of  IOP lowering capacity or safety [14]. Another parallel-group, 
investigator masked study in patients with POAG or ocular hyper-
tension has shown that latanoprost in a preservative free formula-
tion features the same IOP lowering capacity as the formulation 
containing benzalkonium chloride, but with better tolerability 
[15]. Preservative free bimatoprost and travoprost also showed 
non-inferiority compared to the preservative containing formula-
tions in terms of  IOP lowering potential in randomized, double 
masked studies [16, 17]. Fixed combinations containing no pre-
servatives also have been found to be as effective in lowering IOP 
as preservative containing formulations. This has been shown in 
randomized, double masked trials for travoprost 0.004%/timolol 
0.5%-fixed combination as well as for dorzolamide/timolol fixed 
combination [18, 19].
The data from the current study indicate that preservative free 
tafluprost leads to a pronounced decrease in IOP after a 4 and 8 
weeks observation period. In addition, our experiment shows that 
preservative free tafluprost was well tolerated and no severe side 
effects were observed.
The European Glaucoma Society states the IOP lowering poten-
tial of  prostaglandins to be between 25 and 35% from the initial 
value [20]. This is in concordance with the present study, where 
tafluprost decreased IOP in the range of  32% to 34% in the se-
lected study population, which corresponds to an absolute IOP 
decrease of  about 10mmHg. This absolute decrease in IOP is 
slightly higher than observed in other studies investigating the ef-
fect of  tafluprost on IOP [21-23]. In treatment naïve patients with 
different forms of  open angle glaucoma or OHT, 12 weeks treat-
ment with tafluprost decreased IOP by 28.8% [24]. A study in a 
very heterogenous group of  544 patients with glaucoma or OHT 
found an IOP lowering potential of  tafluprost of  21.1% after 12 
weeks treatment. It has to be noted that in this study, 91.8% of  
the patients were already under treatment and were either only 
switched to tafluprost with no wash-out period or tafluprost was 
added to the existing therapy [25]. When comparing our results 
with the results of  these trials, it has, however, to be mentioned 
that all of  the above mentioned studies included patients with 
considerably lower IOPs at baseline than in the current study.
One of  the strength of  the current study is that it was designed 
to investigate the IOP lowering potential in patients with high 
intraocular pressures. This is of  clinical relevance, given that es-
pecially patients with high IOPs require a safe and pronounced 
IOP lowering therapy. To ensure comparable conditions and to 
fully assess the IOP lowering potential all patients had to undergo 
a washout phase of  2-4 weeks. However, because of  ethical rea-
sons, the washout phase was limited to a maximum of  4 weeks, 
which allows for the washout of  the drug without posing a risk of  
long term increase of  IOP.
One limitation of  our study is that the study lacks a control group. 
Thus, we cannot determine how the IOP lowering potential of  
preservative free tafluprost compares to other IOP lowering 
drugs.
Conclusion
In conclusion, our results show that in patients with high IOPs 
preservative free tafluprost is safe and leads to a pronounced de-
crease of  IOP during an 8 week treatment period. Further stud-
ies are, however, needed to assess the safety and IOP lowering 
potential of  preservative free tafluprost for long-term treatment 
of  glaucoma.
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